证券代码：603567 证券简称：珍宝岛 公告编号：临2025-069 黑龙江珍宝岛药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 221 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 507,558,836 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 53.9384 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 本次会议由公司董事会召集，公司董事长方同华先生主持。本次会议以现场 和网络投票相结合的方式对股东会通知中列明的事项进行了投票表决，表决方式 符合《公司法》及《公司章程》的规定。 (五) 公司董事和董事会秘书的出席情况 1、 公司在任董事6人，出席5人，独立 ...

Group 1 - The core point of the article is that Zhenbao Island (603567.SH) reported a significant decline in its financial performance for the first half of 2025, with total operating revenue of 714 million yuan, a year-on-year decrease of 57.05% [1] - The net profit attributable to shareholders of the parent company was -78.29 million yuan, compared to a net profit of 393 million yuan in the same period last year [1] - The basic earnings per share were -0.0833 yuan, indicating a loss compared to the previous year's earnings [1]

Group 1 - The core viewpoint of the article is that Zhenbao Island (603567) reported a significant decline in its financial performance for the first half of 2025, with a notable drop in revenue and a shift from profit to loss [2] - The company achieved an operating income of 713 million yuan, representing a year-on-year decrease of 57.04% [2] - The net profit attributable to shareholders was -78.29 million yuan, compared to a profit of 393 million yuan in the same period last year, indicating a transition from profit to loss [2] Group 2 - The decrease in net profit is primarily attributed to a reduction in sales scale and an increase in credit impairment losses due to delayed customer payments [2]

Group 1 - The core point of the article is that Zhenbao Island has announced the approval of several proposals, including a special report on the management and actual use of funds raised for the first half of 2025 [1] Group 2 - The announcement was made during the 26th meeting of the fifth board of directors of Heilongjiang Zhenbao Island Pharmaceutical Co., Ltd [1]

Core Points - The company reported a significant decline in revenue and profit for the first half of 2025, with revenue at 713 million yuan, a year-on-year decrease of 57.04% [1] - The net profit attributable to shareholders was -78.29 million yuan, compared to a profit of 393 million yuan in the same period last year, indicating a shift from profit to loss [1] - The decrease in net profit is primarily attributed to reduced sales scale and increased credit impairment losses due to delayed customer payments [1]

Core Viewpoint - The company is poised for a significant value reassessment and growth in the traditional Chinese medicine market, driven by strategic adaptations to new procurement policies and an expanding product pipeline [2][5]. Group 1: Market Trends and Company Performance - The traditional Chinese medicine market is expected to reach approximately 1 trillion yuan by 2025, with the market for traditional Chinese medicine preparations exceeding 500 billion yuan, indicating sustainable growth opportunities for the company [2]. - In the first half of 2025, the company reported revenues of 713 million yuan, reflecting resilience despite challenges such as delayed procurement timelines and declining gross margins [2]. - The company's net profit turned negative primarily due to the postponement of procurement for traditional Chinese medicine, leading to a decrease in revenue and gross profit year-on-year [2]. Group 2: Strategic Initiatives and Innovations - The company has secured multiple core products for procurement, including injectable blood stasis drugs, which are expected to cover a market share exceeding 30 billion yuan, enhancing revenue prospects for the second half of 2025 [5]. - The "Procurement 2.0 Era" aligns with the company's robust operational framework, which includes an efficient supply chain covering research, production, and distribution [5]. - The company is actively pursuing innovation in drug development, with ongoing clinical trials for new traditional Chinese medicine products and collaborations in the biopharmaceutical sector [7][9]. Group 3: E-commerce and Market Expansion - The company is strategically targeting the high-end market and grassroots healthcare institutions, leveraging its established customer and channel resources to enhance sales post-procurement [9]. - E-commerce sales in China have seen significant growth, with online pharmaceutical sales projected to reach 717.7 billion yuan in 2024, prompting the company to strengthen its online presence through strategic partnerships [10]. - The company aims to achieve online retail sales of 25 million yuan in the latter half of 2025, reflecting its commitment to expanding its e-commerce footprint [10].

[Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) This section provides important declarations from the board of directors regarding report accuracy and outlines risk statements, emphasizing forward-looking statements are not commitments [Board Statement and Profit Distribution](index=2&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%8F%8A%E8%91%A3%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E4%BF%9D%E8%AF%81%E5%8D%8A%E5%B9%B4%E5%BA%A6%E6%8A%A5%E5%91%8A%E5%86%85%E5%AE%B9%E7%9A%84%E7%9C%9F%E5%AE%9E%E6%80%A7%E3%80%81%E5%87%86%E7%A1%AE%E6%80%A7%E3%80%81%E5%AE%8C%E6%95%B4%E6%80%A7%EF%BC%8C%E4%B8%8D%E5%AD%98%E5%9C%A8%E8%99%9A%E5%81%87%E8%AE%B0%E8%BD%BD%E3%80%81%E8%AF%AF%E5%AF%BC%E6%80%A7%E9%99%88%E8%BF%B0%E6%88%96%E9%87%8D%E5%A4%A7%E9%81%97%E6%BC%8F%EF%BC%8C%E5%B9%B6%E6%89%BF%E6%8B%85%E4%B8%AA%E5%88%AB%E5%92%8C%E8%BF%9E%E5%B8%A6%E7%9A%84%E6%B3%95%E5%BE%8B%E8%B4%A3%E4%BB%BB) The board of directors and senior management guarantee the report's truthfulness, accuracy, and completeness, assuming legal responsibility - The board of directors and senior management guarantee the report's truthfulness, accuracy, and completeness, and assume legal responsibility[3](index=3&type=chunk) - This semi-annual report is unaudited, and the company's head, chief accountant, and head of accounting department declare the financial report is true, accurate, and complete[3](index=3&type=chunk) - There is no profit distribution plan or capital reserve to share capital conversion plan for the current reporting period[3](index=3&type=chunk) [Risk Statement and Significant Risk Disclosures](index=2&type=section&id=%E5%85%AD%E3%80%81%E5%89%8D%E7%9E%BB%E6%80%A7%E9%99%88%E8%BF%B0%E7%9A%84%E9%A3%8E%E9%99%A9%E5%A3%B0%E6%98%8E) Forward-looking statements regarding future plans and development strategies in this report do not constitute actual commitments, and investors should be aware of investment risks - Forward-looking statements do not constitute actual commitments, and investors should be aware of investment risks[3](index=3&type=chunk) - There were no particularly significant risks materially affecting the company's production and operations during the reporting period; specific risks and countermeasures are detailed in Section III[4](index=4&type=chunk) [Section I Definitions](index=4&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) This section defines key terms used throughout the report, ensuring clarity and accurate understanding of the content [Definitions of Common Terms](index=4&type=section&id=%E5%B8%B8%E7%94%A8%E8%AF%8D%E8%AF%AD%E9%87%8A%E4%B9%89) This section provides definitions for common terms used in the report, including company abbreviation, controlling shareholder, GSP, GAP, "689" quality standards, IND, SRM platform, centralized procurement policies, ADC drugs, CDE, PCT pathway, MES system, B2C, and the reporting period, to ensure accurate understanding of the report's content - The reporting period refers to January 1, 2025, to June 30, 2025[12](index=12&type=chunk) - Key terms such as the Company, controlling shareholder, GSP, GAP, "689" quality standards, and centralized procurement policies are clearly defined[12](index=12&type=chunk) [Section II Company Profile and Key Financial Indicators](index=4&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section presents the company's basic information, stock details, and a comprehensive overview of its key accounting data and financial performance [Company Basic Information](index=4&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E4%BF%A1%E6%81%AF) This section introduces the company's Chinese name, abbreviation, foreign name and acronym, and legal representative Yan Jiujiang, along with contact information for the Board Secretary Zhang Zhongfang, and the company's registered address, office address, and website Company Basic Information | Indicator | Content | | :--- | :--- | | Chinese Name | 黑龙江珍宝岛药业股份有限公司 | | Chinese Abbreviation | 珍宝岛 | | Legal Representative | 闫久江 | | Registered Address | 黑龙江省鸡西市虎林市虎林镇红星街72号 | | Office Address | 黑龙江省哈尔滨市平房区烟台一路8号 | | Company Website | http://www.zbdzy.com | [Information Disclosure and Stock Overview](index=5&type=section&id=%E5%9B%9B%E3%80%81%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E5%8F%8A%E5%A4%87%E7%BD%AE%E5%9C%B0%E7%82%B9%E5%8F%98%E6%9B%B4%E6%83%85%E5%86%B5%E7%AE%80%E4%BB%8B) The company designates Shanghai Securities News, China Securities Journal, Securities Times, and Securities Daily as its information disclosure newspapers, with the semi-annual report published on www.sse.com.cn and available at the company's board office - The company's information disclosure newspapers are Shanghai Securities News, China Securities Journal, Securities Times, and Securities Daily, with the website being www.sse.com.cn[15](index=15&type=chunk) Company Stock Overview | Stock Type | Listing Exchange | Stock Abbreviation | Stock Code | | :--- | :--- | :--- | :--- | | A-share | Shanghai Stock Exchange | 珍宝岛 | 603567 | [Key Accounting Data and Financial Indicators](index=5&type=section&id=%E4%B8%83%E3%80%81%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) During the reporting period, the company's operating revenue significantly decreased by **57.04%** to **713.41 million yuan**, with total profit, net profit attributable to parent company shareholders, and non-recurring net profit all turning from profit to loss, decreasing by **122.81%**, **119.90%**, and **123.14%** respectively, while net cash flow from operating activities turned positive and increased year-on-year, primarily due to delayed national centralized procurement for traditional Chinese medicines, reduced shipments, lower product prices, decreased sales scale, and increased credit impairment losses Key Accounting Data (January-June 2025) | Indicator | Current Period (Jan-Jun) (yuan) | Prior Year Period (yuan) | YoY Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 713,410,892.19 | 1,660,604,867.40 | -57.04 | | Total Profit | -114,408,659.28 | 501,667,245.15 | -122.81 | | Net Profit Attributable to Parent Company Shareholders | -78,289,896.49 | 393,331,967.75 | -119.90 | | Net Cash Flow from Operating Activities | -62,101,205.93 | -211

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-068 黑龙江珍宝岛药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 5 日中午 12:00 前，将关注的问题以电子邮件的 形式发送至黑龙江珍宝岛药业股份有限公司（以下简称"公司"）董事会办公室 邮箱（zbddsh@zbdzy.com），公司将结合实际情况，在信息披露允许的范围内， 就投资者普遍关注的问题在说明会上进行回复。 公司于 2025 年 8 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了 《黑龙江珍宝岛药业股份有限公司 2025 年半年度报告》全文及摘要，为便于广 大投资者更全面深入地了解公司财务状况与经营情况，公司将于 2025 年 9 月 5 日（星期五）下午 15:30-16:30 召开 2025 年半年度业绩说明会。现将有关事项 公告如下： 一、业绩说明会类型 本次业绩说明会将采用网络互动方式召开，公司将针对 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-067 黑龙江珍宝岛药业股份有限公司 关于 2025 年半年度募集资金存放、管理与实际使用 情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于核准黑龙江珍宝岛药业股份有限 公司非公开发行股票的批复》（证监许可[2021]338 号）核准，黑龙江珍宝岛药 业股份有限公司（以下简称"公司"或"珍宝岛"）非公开发行人民币普通股 （A 股）92,803,592 股，发行价格为 13.34 元/股，募集资金总额为人民币 1,237,999,917.28 元,扣除本次发行费用人民币 20,759,785.06 元（不含税） 且不包括人民币普通股（A 股）发行申购资金于冻结期间产生的利息收入后， 募集资金净额为人民币 1,217,240,132.22 元，上述募集资金已于 2021 年 10 月 22 日全部到位，中准会计师事务所（特殊普通合伙）对本次非公开发行股票募 集资金到位情况进行了验证，并出具《验 ...

Group 1 - The company reported a revenue of 713 million yuan for the first half of 2025, representing a year-on-year decline of 57.04% [1] - The net profit for the company was a loss of 78.29 million yuan, compared to a net profit of 393 million yuan in the same period last year [1]